Potentially disruptive technologies
We have three highly differentiated technologies focused on next generation anthracycline, immune/transcription modulators and metabolism/glycosylation inhibitors. From those three core technologies, we have six potential oncology drug candidates.
Attacking the most difficult cancers
We are developing treatments for rare and difficult cancers such as acute myeloid leukemia (“AML”); glioblastoma, brain tumors; cutaneous T-cell lymphoma (“CTCL”), a deadly form of skin cancer; and pancreatic cancer.
Relationships with world-class cancer centers
Critical to our efforts is leveraging our continued collaborations and partnerships with leading cancer centers like MD Anderson Cancer Center, Emory University, the Mayo Clinic and others.
“We are extremely excited with the milestones achieved to this point and the ones coming up could be literally game-changing for us. This time last year we had just commenced our very first clinical trial, one drug, and one clinical trial. Now, we have three drugs in four clinical trials under way with a fifth clinical trial that may start before year end. We believe we have the potential to report meaningful data on a quarterly basis going forward. We are highly focused on developing multiple shots on goal to attack highly resistant cancers, either in monotherapy applications or in combination drug therapies. And this last point is important in that we can potentially devise tailored combinations to address rare and difficult cancers from numerous angles and give hope to those who have exhausted currently available therapies.”
A comprehensive collection of scientific papers and publications supporting our portfolio claims.
Our Scientific Advisory Board is part of the Moleculin brain trust. Their expertise and guidance have enabled us to successfully proceed in the development of our highly differentiated compounds.
On October 29, 2019, Moleculin announced the presentation of a poster at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference documenting the high activity of Annamycin against AML.
